{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.8","upperLimit":"44.4","value":"35.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"137"}],"units":"Participants"}],"description":"ORR is defined as the proportion of participants with a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an intravenous (IV) infusion of Dato DXd administered at a dose of 6.0 mg/kg every 3 weeks (Q3W) on Day 1 of each 21-day cycle.","id":"OG000","title":"Dato DXd 6.0 mg/kg Q3W"}],"paramType":"NUMBER","populationDescription":"Outcome Measure was assessed in the Full Analysis Set, which includes all subjects who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.","title":"Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR)","type":"PRIMARY","unitOfMeasure":"percentage of participants"}